Stockscreener 앱 받기
6.46
8.21%
0.49
시장 영업 전:
6.32
-0.14
-2.17%
전일 마감가:
$5.97
열려 있는:
$6.03
하루 거래량:
125.76K
Relative Volume:
2.25
시가총액:
$62.56M
수익:
$1.15M
순이익/손실:
$-46.90M
주가수익비율:
-1.2873
EPS:
-5.0182
순현금흐름:
$-42.37M
1주 성능:
-0.46%
1개월 성능:
-15.45%
6개월 성능:
-58.16%
1년 성능:
-11.75%
1일 변동 폭
$5.92
$6.78
1주일 범위
$5.31
$6.80
52주 변동 폭
$5.31
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
6.46 | 54.42M | 1.15M | -46.90M | -42.37M | -5.0182 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-08 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-04-21 | 개시 | JP Morgan | Neutral |
| 2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-30 | 개시 | Jefferies | Hold |
| 2018-10-22 | 개시 | Chardan Capital Markets | Buy |
| 2017-10-13 | 개시 | Oppenheimer | Outperform |
| 2017-08-04 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-01 | 재확인 | FBR & Co. | Outperform |
| 2016-08-12 | 재확인 | FBR Capital | Outperform |
| 2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | 재확인 | H.C. Wainwright | Buy |
| 2016-07-29 | 재개 | H.C. Wainwright | Buy |
| 2016-03-30 | 개시 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | Guggenheim | Buy |
| 2016-01-25 | 개시 | H.C. Wainwright | Buy |
| 2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | 개시 | Canaccord Genuity | Buy |
| 2015-07-21 | 개시 | Goldman | Neutral |
| 2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Seres Therapeutics (MCRB) Faces Sharp Decline, Tests Key Support LevelsETH Profile - newsline.com
We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate - Yahoo Finance
Seres Therapeutics (MCRB) Slips 2.62% as Shares Test Key Support at $6.00Bull Pennant - newsline.com
Cambridge biotech surrenders half its lab space amid cash crunch - The Business Journals
MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits
Seres Therapeutics (MCRB) Secures Cash Runway Extension Through Key Transactions - GuruFocus
Seres Therapeutics Secures $25M from Nestlé, Restructures Lease to Extend Cash Runway Into 2027 - Minichart
Seres Therapeutics secures $25M from Nestlé Health Science By Investing.com - Investing.com South Africa
Seres Therapeutics Reshapes Finances with Lease Restructuring - TipRanks
Seres Therapeutics Extends Cash Runway to 2027 Through Financial Restructuring and Lease Adjustments - geneonline.com
Seres Therapeutics Secures $25 Million from Nestlé Health Science and Reduces Facility Costs to Enhance Financial Position - Quiver Quantitative
Seres Therapeutics Announces Two Transactions To Strengthen Balance Sheet, Reduce On-Going Lease Costs And Extend Projected Operating Cash Runway Well Into The First Quarter Of 2027 - TradingView
Seres Therapeutics secures $25M from Nestlé Health Science - Investing.com
Seres Therapeutics (Nasdaq: MCRB) extends cash runway into 2027 - Stock Titan
Drugmaker Seres gets $25M from Nestlé, cuts Boston-area lab lease costs - Stock Titan
Seres Therapeutics, Inc. Files 8-K Current Report with SEC Detailing Corporate Information (May 30, 2026) - Minichart
[8-K] Seres Therapeutics, Inc. Reports Material Event - Stock Titan
Seres Therapeutics (MCRB) Slips 3.4%, Testing Key Support at $6.95Range Breakout - newsline.com
Seres Therapeutics (MCRB) Declines 2.18% as Stock Approaches Key SupportHigh Reward Trades - newsline.com
MCRB News | SERES THERAPEUTICS INC (NASDAQ:MCRB) - ChartMill
Seres Therapeutics (MCRB) Edges Higher Amid Steady Support and Resistance DynamicsDark Pool Volume - The Legal Advocate
Seres Therapeutics (MCRB) Declines 5.93% as Selling Pressure IntensifiesLow Risk Entry Stocks - The Legal Advocate
MCRB Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues R&D FocusEarnings Beat Streak - The Legal Advocate
MCRB SEC FilingsSeres Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Seres Therapeutics (MCRB) Q1 2026 Miss: What Went WrongEPS Surprise History - Newser
Seres Therapeutics (MCRB) Q1 2026 Miss: Should Investors Be Worried?EPS Estimate Trend - The Legal Advocate
MCRB: AI-driven microbiome therapeutics pipeline advances toward key clinical and commercial milestones - TradingView
Teresa L. Young sells shares; MCRB (NASDAQ: MCRB) files Form 144 notice - Stock Titan
Officer at Seres Therapeutics (NASDAQ: MCRB) sells 79 shares under 10b5-1 tax plan - Stock Titan
Seres Therapeutics (MCRB) officer sells shares after RSU vesting under 10b5-1 plan - Stock Titan
Microbiome Therapeutics Market Size, Share | Forecast [2034] - Fortune Business Insights
Seres Therapeutics stock (US81750R1023): Q1 2026 results and private placement - AD HOC NEWS
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference - The Manila Times
How to watch Seres Therapeutics’ BioConnect investor presentation - Stock Titan
How Seres Therapeutics (MCRB) balances short term and long term focus | Q1 2026: EPS Misses ViewsNCAV - Newser
MSN Money - MSN
The working capital efficiency at Seres Therapeutics (MCRB) | Q1 2026: EPS Misses EstimatesProfit Margin - newser.com
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Seres Therapeutics 1Q 2026: Revenue $358K, EPS $(2.08) — 10-Q Summary - TradingView
Seres Therapeutics (NASDAQ: MCRB) Q1 2026 loss and going-concern risk - Stock Titan
Seres Therapeutics: Q1 Earnings Snapshot - marketscreener.com
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics (Nasdaq: MCRB) Q1 2026 results and cash runway - Stock Titan
Seres awaits SER-155 data in weeks with cash through Q3 - Stock Titan
Seres presents preclinical data on IBD drug candidate SER-603 - Investing.com UK
Seres presents preclinical data on IBD drug candidate SER-603 By Investing.com - Investing.com South Africa
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease - The Manila Times
Experimental IBD microbiome therapy earns DDW poster honor - Stock Titan
Seres Therapeutics Presents Preclinical Data at Digestive - GlobeNewswire
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Seres Therapeutics Inc 주식 (MCRB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shaff Eric D. | Director |
May 18 '26 |
Sale |
7.53 |
259 |
1,950 |
12,040 |
| DesRosier Thomas | See Remarks |
May 18 '26 |
Sale |
7.53 |
79 |
595 |
7,954 |
| Henn Matthew R | See Remarks |
May 18 '26 |
Sale |
7.53 |
77 |
580 |
7,838 |
| Brady Kelly | See Remarks |
May 18 '26 |
Sale |
7.53 |
59 |
444 |
8,562 |
2.60%
0.94%
자본화:
|
볼륨(24시간):